MCID: INT025
MIFTS: 34

Intermittent Explosive Disorder malady

Mental diseases category

Aliases & Classifications for Intermittent Explosive Disorder

About this section

Aliases & Descriptions for Intermittent Explosive Disorder:

Name: Intermittent Explosive Disorder 10 12 65
Explosive Personality Disorder 10 65
 
Disruptive, Impulse Control, and Conduct Disorders 36


Classifications:



External Ids:

Disease Ontology10 DOID:12401
ICD9CM29 312.34, 301.3
MeSH36 D007174

Summaries for Intermittent Explosive Disorder

About this section
Disease Ontology:10 An impulse control disorder that involves the episodic inability to control violent impulses with a disproportionate degree of aggressiveness.

MalaCards based summary: Intermittent Explosive Disorder, also known as explosive personality disorder, is related to psychotic disorder and obsessive-compulsive disorder. An important gene associated with Intermittent Explosive Disorder is SLC6A4 (Solute Carrier Family 6 (Neurotransmitter Transporter), Member 4), and among its related pathways are Sympathetic Nerve Pathway (Pre- and Post- Ganglionic Junction) and Sympathetic Nerve Pathway (Neuroeffector Junction). Affiliated tissues include brain, and related mouse phenotypes are homeostasis/metabolism and behavior/neurological.

Wikipedia:68 Intermittent explosive disorder (sometimes abbreviated as IED) is a behavioral disorder characterized by... more...

Related Diseases for Intermittent Explosive Disorder

About this section

Diseases related to Intermittent Explosive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 86)
idRelated DiseaseScoreTop Affiliating Genes
1psychotic disorder30.2HTR1A, HTR2A, HTR7, SLC6A4
2obsessive-compulsive disorder30.0HTR1A, HTR1B, HTR2A, SLC6A4, TPH1
3attention deficit-hyperactivity disorder29.6CHRFAM7A, CHRNA7, HTR1A, HTR1B, HTR2A, SLC6A4
4impulse control disorder10.5
5conduct disorder10.5
6personality disorder10.5
7drug psychosis10.4
8spastic ectropion10.3HTR2A, SLC6A4
9panophthalmitis10.3HTR2A, SPG21
10aleukemic leukemia cutis10.3HTR2A, SLC6A4
11trachea leiomyoma10.3HTR2A, SLC6A4
12giant cell tumor10.2HTR2A, SLC6A4
13prader-willi syndrome10.2
14bipolar disorder10.2
15osteoarthritis10.2
16pyromania10.2
17avoidant personality disorder10.2
18obsessive-compulsive personality disorder10.2
19borderline personality disorder10.2
20spastic diplegia10.2
21oppositional defiant disorder10.2
22premenstrual tension10.2
23disease of mental health10.2
24learning disability10.2
25physical disorder10.2
26speech disorder10.2
27gastrointestinal tularemia10.2HTR2A, TPH1
28subvalvular aortic stenosis10.2HTR1A, HTR2A
29central nervous system immature teratoma10.2HTR1A, HTR2A
30leech infestation10.1HTR2A, SLC6A4
31hard palate cancer10.1HTR2A, HTR7
32phosphorus metabolism disease10.1HTR1A, HTR2A, SLC6A4
33familial glomangioma10.1HTR1A, HTR2A, SLC6A4
34melanotic neuroectodermal tumor10.1HTR1A, HTR2A, SLC6A4
35acute eustachian salpingitis10.1HTR2A, HTR7
36hereditary myopathy with lactic acidosis due to iscu deficiency10.1HTR1A, HTR2A, SLC6A4
37neonatal myasthenia gravis10.1HTR1A, HTR2A, SLC6A4
38steatorrhea10.1HTR2A, HTR7
39hodgkin's lymphoma, lymphocytic-histiocytic predominance10.1HTR1A, HTR2A, SLC6A4
40functioning pituitary adenoma10.1HTR2A, HTR7
41postsurgical hypothyroidism10.1HTR2A, HTR7, SLC6A4
42writing disorder10.1HTR2A, HTR7
43nicotine dependence, protection against10.1CHRNA7, HTR2A, TPH1
44dependent personality disorder10.1HTR2A, HTR7, SLC6A4
45maxillary sinus squamous cell carcinoma10.1HTR2A, NPY
46pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma10.0HTR1A, SLC6A4
47autosomal dominant partial epilepsy with auditory features10.0CHRFAM7A, CHRNA7
48acute thyroiditis10.0HTR2A, NPY
49lactocele10.0HTR2A, HTR7
50simultanagnosia10.0HTR2A, HTR7

Graphical network of the top 20 diseases related to Intermittent Explosive Disorder:



Diseases related to intermittent explosive disorder

Symptoms for Intermittent Explosive Disorder

About this section

Drugs & Therapeutics for Intermittent Explosive Disorder

About this section

Drugs for Intermittent Explosive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Guanfacineapproved, investigationalPhase 45229110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine
Guanfacine (INN)
Guanfacine Hydrochloride
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tenex
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
2
Naratriptanapproved, investigationalPhase 414143388-64-1, 121679-13-84440
Synonyms:
121679-13-8
AC-5013
AC1L1I6A
Amerge
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
 
LS-83062
MolPort-005-932-823
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
NCGC00181786-01
Naramig
Naramig (TN)
Naratriptan
Naratriptan (INN)
Naratriptanum
S1488_Selleck
UNII-QX3KXL1ZA2
naratriptan
naratriptanum
3
SerotoninPhase 4, Phase 3, Phase 2285350-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
4Adrenergic alpha-2 Receptor AgonistsPhase 4732
5
Risperidoneapproved, investigationalPhase 3579106266-06-25073
Synonyms:
106266-06-2
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydro-pyrido[
3-(2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl)-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one
3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-[2-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,
3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
AB00514010
AC-1306
AC1L1JJU
BIDD:GT0262
BRD-K53857191-001-04-5
BRN 4891881
Belivon
Bio-0092
Buspirone
C23H27FN4O2
CAS-106266-06-2
CHEBI:8871
CHEMBL85
CID5073
CPD000466323
Consta, Risperdal
D00426
D018967
DB00734
EU-0101074
HMS1571M19
HMS2051H07
HMS2089C22
HSDB 7580
I01-1156
Jsp000573
KS-1106
L000510
LS-134196
Lopac-R-118
MLS000759429
MLS001165758
MLS001424081
MolPort-002-885-858
NCGC00015883-01
 
NCGC00015883-02
NCGC00015883-03
NCGC00094352-01
NCGC00094352-02
NCGC00094352-03
NCGC00179257-01
Prestwick0_001029
Prestwick1_001029
R 62 766
R 64 766, Risperdal, Risperidone
R 64,766
R 64766
R-118
R-64,766
R-64-766
R-64766
R64,766
R64766
Rispen
Risperdal
Risperdal (TN)
Risperdal Consta
Risperdal M-Tab
Risperdal M-tab
Risperidal
Risperidal M-Tab
Risperidona
Risperidona [Spanish]
Risperidone
Risperidone (JAN/USAN/INN)
Risperidone (RIS)
Risperidone M-tab
Risperidone [USAN:BAN:INN]
Risperidone, placebo
Risperidonum
Risperidonum [Latin]
Risperin
Rispolept
Rispolin
S1615_Selleck
SAM001246595
SMR000466323
SPBio_003078
STK646402
Sequinan
Spiron
TL8000230
UNII-L6UH7ZF8HC
risperdone
risperidone
6
DopamineapprovedPhase 3281462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
7
FluoxetineapprovedPhase 221754910-89-33386
Synonyms:
(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+/-)-Fluoxetine
(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
52341-67-0
54910-89-3
57226-07-0
59333-67-4 (hydrochloride)
AB00053774
AC-14564
AC1L1FTH
AKOS003663021
Adofen
Animex-On
BPBio1_000354
BPBio1_000509
BRD-A31159102-001-01-9
BRD-A31159102-003-05-6
BSPBio_000461
BSPBio_003375
Bio-0787
Biomol-NT_000152
C17H18F3NO
CHEBI:5118
CHEMBL41
CID3386
D00326
DB00472
Deprex
DivK1c_006819
Eufor
Floxetine
Fluctin
Fluoxeren
Fluoxetin
Fluoxetina
Fluoxetina [INN-Spanish]
Fluoxetina [Spanish]
Fluoxetine
Fluoxetine (TN)
Fluoxetine (USAN/INN)
Fluoxetine Hcl
Fluoxetine Hydrochloride
Fluoxetine [USAN:INN:BAN]
Fluoxetinum
 
Fluoxetinum [INN-Latin]
Fluoxétine
Fluval
Fontex
Foxetin
HMS2090H14
KBio1_001763
KBio2_002159
KBio2_004727
KBio2_007295
KBio3_002595
KBioGR_001166
KBioSS_002159
L000931
LS-31040
Lilly-110140
Lopac0_000558
Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine
MolPort-001-683-482
N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
NCGC00015428-10
NCGC00024879-03
NCGC00024879-04
NSC283480
Portal
Prestwick0_000511
Prestwick1_000511
Prestwick2_000511
Prestwick3_000511
Prozac
Prozac Weekly
Pulvules
Reconcile
Reneuron
SPBio_001815
SPBio_002382
STK734483
Sarafem
SpecPlus_000723
Spectrum2_001658
Spectrum3_001648
Spectrum4_000613
Spectrum5_001518
Spectrum_001679
TL8003595
UNII-01K63SUP8D
dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
fluoxetine
fluoxetine (Prozac)
nchembio.534-comp2
8VasopressinsPhase 1, Phase 2159
9Arginine VasopressinPhase 1, Phase 2163

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive DisorderRecruitingNCT02048241Phase 4
2Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
3Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.CompletedNCT00399698Phase 3
4Psychotherapy for Intermittent Explosive DisorderCompletedNCT00667212Phase 2
5A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive DisorderCompletedNCT00078754Phase 2
6A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IEDCompletedNCT00127400Phase 2
7Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive DisorderRecruitingNCT02055638Phase 1, Phase 2

Search NIH Clinical Center for Intermittent Explosive Disorder


Cochrane evidence based reviews: Disruptive, Impulse Control, and Conduct Disorders

Genetic Tests for Intermittent Explosive Disorder

About this section

Anatomical Context for Intermittent Explosive Disorder

About this section

MalaCards organs/tissues related to Intermittent Explosive Disorder:

33
Brain

Animal Models for Intermittent Explosive Disorder or affiliated genes

About this section

MGI Mouse Phenotypes related to Intermittent Explosive Disorder:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053766.6ADRB1, CGA, CHRNA7, HTR1A, HTR7, NPY
2MP:00053866.3CHRNA7, HTR1A, HTR1B, HTR2A, HTR7, NPY

Publications for Intermittent Explosive Disorder

About this section

Articles related to Intermittent Explosive Disorder:

(show top 50)    (show all 69)
idTitleAuthorsYear
1
Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. (26277033)
2015
2
Verbal versus physical aggression in Intermittent Explosive Disorder. (25534757)
2015
3
The coherence and correlates of intermittent explosive disorder amongst West Papuan refugees displaced to Papua New Guinea. (25754605)
2015
4
Emotional intelligence and impulsive aggression in Intermittent Explosive Disorder. (25477263)
2015
5
The experience of aggressive outbursts in Intermittent Explosive Disorder. (25541537)
2015
6
Doing Psychiatry Right: A Case of Severe Avoidant Personality Disorder with Obsessive-compulsive Personality Disorder, Obsessive Compulsive Disorder, Intermittent Explosive Disorder and Sexual Paraphilias. (25035563)
2014
7
Emotion regulation deficits in intermittent explosive disorder. (25403171)
2014
8
Self-harm behavior among individuals with intermittent explosive disorder and personality disorders. (25300440)
2014
9
Intermittent explosive disorder: associations with PTSD and other Axis I disorders in a US military veteran sample. (24907536)
2014
10
Common and distinct neural correlates of inhibitory dysregulation: stroop fMRI study of cocaine addiction and intermittent explosive disorder. (25106072)
2014
11
Relationship between psychopathy, aggression, anger, impulsivity, and intermittent explosive disorder. (24760575)
2014
12
Validity of the new A1 and A2 criteria for DSM-5 intermittent explosive disorder. (24321204)
2014
13
Elevated Plasma Oxidative Stress Markers in Individuals with Intermittent Explosive Disorder and Correlation with Aggression in Humans. (24582164)
2014
14
Achieving convergence between a community-based measure of explosive anger and a clinical interview for intermittent explosive disorder in Timor-Leste. (23835102)
2013
15
Elevated Plasma Inflammatory Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans. (24352431)
2013
16
Intermittent explosive disorder amongst women in conflict affected Timor-Leste: associations with human rights trauma, ongoing violence, poverty, and injustice. (23950885)
2013
17
The prevalence and correlates of intermittent explosive disorder in Iraq. (22443168)
2012
18
Intermittent explosive disorder in the National Comorbidity Survey Replication Adolescent Supplement. (22752056)
2012
19
Striatal activity in borderline personality disorder with comorbid intermittent explosive disorder: sex differences. (22464337)
2012
20
Epidemiological aspects of intermittent explosive disorder in Japan; prevalence and psychosocial comorbidity: findings from the World Mental Health Japan Survey 2002-2006. (20709410)
2011
21
Treating intermittent explosive disorder. Emerging data show medication and cognitive behavioral therapy may help some patients. (21786470)
2011
22
Latent structure of intermittent explosive disorder in an epidemiological sample. (20064645)
2010
23
A case of intermittent explosive disorder. (21694793)
2010
24
Expert witness claimed that a defendant had "intermittent explosive disorder," GMC hears. (21147742)
2010
25
Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder. (19767013)
2010
26
Deep brain stimulation of the orbitofrontal projections for the treatment of intermittent explosive disorder. (20672913)
2010
27
Intermittent explosive disorder in South Africa: prevalence, correlates and the role of traumatic exposures. (19225243)
2009
28
A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. (19389333)
2009
29
P3a and mismatch negativity in individuals with moderate Intermittent Explosive Disorder. (19463896)
2009
30
The relationship between impulsive verbal aggression and intermittent explosive disorder. (17654692)
2008
31
Cognitive-behavioral therapy for intermittent explosive disorder: a pilot randomized clinical trial. (18837604)
2008
32
Lifetime and 12-month intermittent explosive disorder in Latinos. (18444735)
2008
33
EEG correlates of moderate intermittent explosive disorder. (18032100)
2008
34
Prevalence of suicidal and self-injurious behavior among subjects with intermittent explosive disorder. (18221794)
2008
35
Intranasal ketamine for intermittent explosive disorder: a case report. (17854260)
2007
36
Intermittent explosive disorder-integrated research diagnostic criteria: convergent and discriminant validity. (16153657)
2006
37
Intermittent explosive disorder and impulsive aggression: the time for serious study is now. (14738696)
2004
38
Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. (15291659)
2004
39
Intermittent explosive disorder: epidemiology, diagnosis and management. (12096933)
2002
40
Psychological characteristics of aggressive drivers with and without intermittent explosive disorder. (12375724)
2002
41
Intermittent explosive disorder and other psychiatric comorbidity among court-referred and self-referred aggressive drivers. (12051483)
2002
42
Validation of the Interview Module for Intermittent Explosive Disorder (M-IED) in children and adolescents: a pilot study. (11311929)
2001
43
Intermittent explosive disorder. (11122935)
2000
44
Recognition and treatment of DSM-IV intermittent explosive disorder. (10418808)
1999
45
DSM-IV intermittent explosive disorder: a report of 27 cases. (9590677)
1998
46
Hypothalamic lesions and intermittent explosive disorder. (1627961)
1992
47
The diagnosis of intermittent explosive disorder in violent men. (2039850)
1991
48
Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient. (3667542)
1987
49
Therapeutic use of propranolol for intermittent explosive disorder. (3546964)
1987
50
Metoprolol for intermittent explosive disorder. (4025634)
1985

Variations for Intermittent Explosive Disorder

About this section

Expression for genes affiliated with Intermittent Explosive Disorder

About this section
Search GEO for disease gene expression data for Intermittent Explosive Disorder.

Pathways for genes affiliated with Intermittent Explosive Disorder

About this section

Pathways related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 13)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.8CHRFAM7A, CHRNA7
29.3ADRB1, NPY
39.2ADRB1, CGA, HTR7
49.0ADRB1, CGA, NPY
58.5ADRB1, CHRFAM7A, CHRNA7, HTR2A, HTR7
6
Show member pathways
8.3ADRB1, HTR1A, HTR1B, NPY
78.3CHRFAM7A, CHRNA7, HTR1A, HTR2A, SLC6A4, TPH1
8
Show member pathways
8.3ADRB1, HTR1A, HTR1B, HTR2A, HTR7
98.1ADRB1, HTR1A, NPY, SLC6A4, TPH1
10
Show member pathways
8.0CHRFAM7A, CHRNA7, HTR1A, HTR1B, HTR2A, HTR7
118.0HTR1A, HTR1B, HTR2A, HTR7, SLC6A4, TPH1
12
Show member pathways
7.3CHRFAM7A, CHRNA7, HTR1A, HTR1B, HTR2A, HTR7
13
Show member pathways
6.5ADRB1, CGA, CHRFAM7A, CHRNA7, HTR1A, HTR1B

GO Terms for genes affiliated with Intermittent Explosive Disorder

About this section

Cellular components related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1acetylcholine-gated channel complexGO:000589210.2CHRFAM7A, CHRNA7
2neuron projectionGO:00430059.1CHRFAM7A, CHRNA7, SLC6A4, TPH1
3integral component of plasma membraneGO:00058877.8ADRB1, HTR1A, HTR1B, HTR2A, HTR7, SLC6A4

Biological processes related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of organ growthGO:004662110.5CGA, SLC6A4
2negative regulation of synaptic transmission, glutamatergicGO:005196710.4HTR1B, HTR2A
3temperature homeostasisGO:000165910.4ADRB1, HTR2A
4adenylate cyclase-inhibiting serotonin receptor signaling pathwayGO:000719810.3HTR1A, HTR1B
5regulation of hormone secretionGO:004688310.2HTR1A, HTR2A
6synaptic transmission, cholinergicGO:000727110.2CHRFAM7A, CHRNA7
7smooth muscle contractionGO:000693910.2HTR2A, HTR7
8bone remodelingGO:004684910.1HTR1B, TPH1
9regulation of behaviorGO:00507959.9HTR1A, HTR1B, HTR2A
10memoryGO:00076139.8CHRNA7, HTR2A, SLC6A4
11regulation of dopamine secretionGO:00140599.7HTR1B, HTR2A
12serotonin receptor signaling pathwayGO:00072109.7HTR1A, HTR2A, HTR7
13circadian rhythmGO:00076239.3HTR7, SLC6A4, TPH1
14vasoconstrictionGO:00423109.2HTR1A, HTR1B, HTR7, SLC6A4
15G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerGO:00071879.0HTR1B, HTR7, NPY
16positive regulation of cell proliferationGO:00082848.8CGA, CHRNA7, CTSH, HTR1A, HTR2A
17synaptic transmissionGO:00072687.8CHRNA7, HTR1B, HTR2A, HTR7, NPY, SLC6A4

Molecular functions related to Intermittent Explosive Disorder according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1serotonin bindingGO:005137810.4HTR1B, HTR2A
2acetylcholine-activated cation-selective channel activityGO:000488910.1CHRFAM7A, CHRNA7
3acetylcholine receptor activityGO:001546410.1CHRFAM7A, CHRNA7
4acetylcholine bindingGO:004216610.1CHRFAM7A, CHRNA7
5drug bindingGO:00081449.5CHRNA7, HTR1B, HTR2A
6serotonin receptor activityGO:00049939.2HTR1A, HTR1B, HTR2A, HTR7
7G-protein coupled receptor activityGO:00049307.2ADRB1, HTR1A, HTR1B, HTR2A, HTR7, NPY

Sources for Intermittent Explosive Disorder

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet